All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
The advanced age of most patients with chronic lymphocytic leukemia (CLL)—a disease for which the median age at diagnosis is 70 years—complicates its management; many of these patients have comorbidities and are on multiple other medications, which must be considered when selecting treatment. Traditional chemotherapy regimens may be intolerable for elderly patients with comorbidities and even newer targeted therapies may not be the best choice for certain patients. The adverse event (AE) profile of Bruton’s tyrosine kinase (BTK) inhibitors, for example, is such that it may be risky for patients with a history of cardiovascular or bleeding issues, and continuous treatment may be interrupted in patients with hypertension, potentially compromising the therapeutic effect of the drug.1
At the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Pinilla-Ibarz, et al. presented a poster with data from a retrospective analysis of the phase 3 UNITY-CLL trial (NCT02612311), which compared the novel anti-CD20 monoclonal antibody ublituximab + the phosphoinositide 3-kinase delta (PI3Kδ) inhibitor umbralisib (U2) with obinutuzumab + chlorambucil in patients with untreated and previously treated CLL. The analysis, which was conducted in patients treated with U2 who had a pre-existing comorbid condition or concomitant medication that could preclude treatment with BTK inhibitors, is summarized below.1
In the UNITY-CLL trial, previously treated and treatment-naïve patients with CLL were randomized 1:1:1:1 to U2, obinutuzumab + chlorambucil, umbralisib monotherapy, or ublituximab monotherapy. Eligibility criteria included age ≥18 years, adequate organ function, and Eastern Cooperative Oncology Group Performance Status score ≤2. More detailed information on the design of the UNITY-CLL trial can be found here.
Patients included in the retrospective analysis had a pre-existing comorbidity or concomitant medication that could potentially preclude treatment with a BTK inhibitor. Pre-existing cardiac or bleeding issues, hypertension, and history of autoimmune disease are potential risk factors for adverse events associated with BTKi therapy (Table 1).
Table 1. Comorbid conditions in UNITY-CLL patients who received U2*
Comorbidities, n (%) |
U2 population |
---|---|
Arrythmia |
31 (15) |
Hypertension and 2 antihypertensives |
45 (22) |
Cardiovascular dysfunction (myocardial infarction, coronary artery |
50 (24) |
History of hemorrhage |
5 (2) |
Arthritis/arthralgia |
46 (22) |
Unique patients |
114 (55) |
U2, ublituximab and umbralisib. |
Regarding concomitant medications, currently available BTKi have shown drug-drug interactions with CYP3A inhibitors and inducers and proton pump inhibitors, and anticoagulant/antiplatelet therapy increases the risk of major hemorrhage when taken concomitantly with BTKi (Table 2).
Table 2. Concomitant medications in UNITY-CLL patients who received U2*
Concomitant medications, n (%) |
U2 population |
Anticoagulant |
9 (4) |
CYP3A4 moderate inhibitor |
7 (3) |
CYP3A4 strong inducer |
2 (1) |
CYP3A4 strong inhibitor |
1 (0.5) |
Dual antiplatelet or anticoagulant |
2 (1) |
Polypharmacy |
5 (2) |
PPI |
37 (18) |
Vitamin K antagonist |
2 (1) |
Unique patients |
53 (26) |
PPI, proton pump inhibitor; U2, ublituximab and umbralisib. |
There were 206 patients in the UNITY-CLL study who received treatment with U2, and of those, 131 (63.6%) met at least one BTKi risk factor criteria (as outlined in the tables above). Among the patients who met at least one risk factor for BTKi treatment, the median age was 69 years (slightly higher than the 67-year median age in the overall cohort). Other disease characteristics were similar to those seen in the overall cohort:
At a median follow-up of 36.7 months, 40% of patients with a BTKi risk factor remain on treatment with U2 vs 37% in the entire U2 treated population. The median progression free survival for patients with a BTKi risk factor was 31.9 months, which was equivalent to the entire U2-treated population, and the overall response rate was slightly higher but not significantly so (88% vs 83%).
Comorbidities and concomitant medications did not increase discontinuation rates in patients receiving U2, discontinuations due to AEs and deaths did not appear to be exacerbated by comorbidities or concomitant medications. There were no significant differences in the incidences of serious AEs or Grade ≥3 AEs (Table 3).
Table 3. UNITY-CLL safety overview*
AE, % (unless |
Entire U2 |
No comorbidity |
Any comorbidity (n = 131) |
≥1 |
≥1 con med |
---|---|---|---|---|---|
Median exposure, |
|
|
|
|
|
Umbralisib |
21 |
21 |
18 |
19 |
21 |
Ublituximab |
21 |
19 |
22 |
21 |
25 |
Patients with ≥1 AE |
100 |
100 |
100 |
100 |
100 |
Serious AEs |
46 |
39 |
50 |
49 |
59 |
Grade ≥3 |
82 |
80 |
83 |
82 |
85 |
Fatal AEs† |
4 |
5 |
3 |
4 |
2 |
AE, adverse event; con med, concomitant medication; U2, ublituximab and umbralisib. |
In this retrospective analysis, patients with at least one BTKi risk factor (thus potentially rendering BTKi therapy unsuitable) who were treated with U2 demonstrated similar efficacy results to those seen in the general population of patients treated with U2 in the UNITY-CLL trial. The comorbidities in these patients did not appear to significantly impact the safety of U2 as evidenced by discontinuation rates similar to that of the overall population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox